Zacks Investment Research lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report published on Thursday morning.
According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
SUPN has been the subject of a number of other reports. Cantor Fitzgerald set a $57.00 price objective on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, January 10th. ValuEngine downgraded Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 6th. Mizuho raised their price objective on Supernus Pharmaceuticals from $61.00 to $63.00 and gave the stock a buy rating in a research report on Monday, December 17th. BidaskClub downgraded Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, February 22nd. Finally, B. Riley set a $65.00 price objective on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Monday, March 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of Hold and an average target price of $55.75.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.19. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. The firm had revenue of $113.50 million for the quarter, compared to analyst estimates of $105.36 million. During the same period last year, the firm posted $0.26 earnings per share. The business’s revenue for the quarter was up 31.4% on a year-over-year basis. On average, sell-side analysts predict that Supernus Pharmaceuticals will post 2.37 earnings per share for the current fiscal year.
In other news, CFO Gregory S. Patrick sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total transaction of $830,600.00. Following the completion of the transaction, the chief financial officer now directly owns 67,896 shares in the company, valued at $2,819,720.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of SUPN. Capital Impact Advisors LLC increased its holdings in Supernus Pharmaceuticals by 8.9% in the fourth quarter. Capital Impact Advisors LLC now owns 44,665 shares of the specialty pharmaceutical company’s stock worth $1,445,000 after purchasing an additional 3,661 shares in the last quarter. American Century Companies Inc. increased its holdings in Supernus Pharmaceuticals by 1.3% in the fourth quarter. American Century Companies Inc. now owns 81,048 shares of the specialty pharmaceutical company’s stock worth $2,692,000 after purchasing an additional 1,001 shares in the last quarter. Geode Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 588,259 shares of the specialty pharmaceutical company’s stock worth $19,541,000 after purchasing an additional 44,268 shares in the last quarter. Norges Bank bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth approximately $24,711,000. Finally, Amalgamated Bank bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth approximately $256,000. Institutional investors own 97.89% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Recommended Story: Understanding Specialty Certificates of Deposit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.